当前授权
机会

HER2 靶向 ADC

新型 HER2 靶向抗体偶联药物，具有差异化的连接子-载荷技术。I 期剂量爬坡已完成；前两个剂量组显示出良好的耐受性。

口服 GLP-1 受体激动剂

每日一次口服 GLP-1 受体激动剂，处于 II 期，用于 2 型糖尿病与肥胖。I 期 PK/PD 数据强劲。正寻求北美商业化合作伙伴。

酶替代疗法

用于溶酶体贮积症的重组酶替代疗法。II 期已完成，主要终点具有统计学显著性。通往 NDA/BLA 的监管路径清晰明确。

IL-17A/F 双特异性抗体

共同靶向 IL-17A 与 IL-17F 的双特异性抗体，用于中重度银屑病与银屑病关节炎。已有 I 期安全性与耐受性数据。

第四代 CAR-T

用于复发/难治性多发性骨髓瘤的新一代装甲 CAR-T 细胞疗法。I/II 期入组进行中；已报告早期疗效信号。

NLRP3 炎性小体抑制剂

具有脑渗透性的选择性 NLRP3 炎性小体抑制剂。在阿尔茨海默病与帕金森病模型中显示体内疗效。正寻求 IND 申报支持研究的合作伙伴或完整受让方。

KRAS G12C 抑制剂

中国制药公司寻求已获批或处于 III 期的 KRAS G12C 抑制剂在中国市场的引进授权权利。拥有强大的商业化基础设施与完整的监管支持。

PCSK9 单克隆抗体

成熟的中国心血管专科公司寻求已获批或后期阶段 PCSK9 抑制剂的引进授权权利。在一、二线城市拥有成熟的商业化团队。

KRAS G12V Inhibitor

US/EU buyer seeking to in-license a KRAS G12V-targeted oncology program. Target-specific mandate open to small molecule or biologic; asset must be IND-cleared or later. Ex-China / global rights preferred.

US/EU buyer disease-area mandate for AL amyloidosis. Small molecule or biologic; preclinical candidate (PCC) stage or later. Mechanism open.

US/EU buyer disease-area mandate for ANCA-associated vasculitis (GPA, MPA, EGPA). Small molecule or biologic; PCC stage or later. Mechanism open.

US/EU buyer disease-area mandate for anemia of chronic kidney disease. Small molecule or biologic; PCC stage or later. Mechanism open.

US/EU buyer disease-area mandate for anemia of inflammatory bowel disease. Small molecule or biologic; PCC stage or later. Mechanism open.

CCR3 Antagonist

US/EU buyer target-interest mandate for CCR3 antagonist programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.

JAG1 Agonist

US/EU buyer target-interest mandate for JAG1 (Jagged-1) agonist programs. Preclinical-stage assets acceptable; indication flexible.

ENTPD1 / CD39 Antagonist

US/EU buyer target-interest mandate for ENTPD1 (CD39) antagonist programs. Preclinical-stage assets acceptable; immuno-oncology focus.

US/EU companies are running an active roadshow to in-license novel, potentially disease-modifying therapies for rare and specialty movement disorders, motor neuron diseases, and rare epilepsies. Open to small and large molecules and siRNA; preclinical-stage assets acceptable and any stage considered. Ex-China / global rights preferred.

TRAIL Agonist

US/EU buyer seeking to in-license TRAIL-agonist programs from PCC through Phase II; indication flexible. Ex-China / global rights preferred.

siRNA / Antisense Oligonucleotide

Well-established US/EU fund seeking siRNA, antisense oligonucleotide, and small-nucleic-acid programs across any disease area; preclinical acceptable. Ex-China / global rights preferred.

US/EU buyer seeking to in-license cardiovascular and kidney disease programs across modalities (small molecule, large molecule, siRNA, peptide, antisense); preclinical acceptable. Ex-China / global rights preferred.

US/EU buyer seeking to in-license programs for Polycythemia Vera. Large molecule, small molecule, siRNA, or peptide; preclinical acceptable. Ex-China / global rights preferred.

US/EU buyer seeking to in-license programs for Von Willebrand Disease. Large molecule, small molecule, siRNA, or peptide; preclinical acceptable. Ex-China / global rights preferred.

US/EU buyer seeking to in-license programs for Warm Autoimmune Hemolytic Anemia. Large molecule, small molecule, siRNA, or peptide; preclinical acceptable. Ex-China / global rights preferred.

Energy expenditure / metabolic (non-appetite-suppression)

US/EU buyer seeking to in-license small-molecule weight-loss programs, oral formulations preferred, that drive weight loss by boosting energy metabolism or energy expenditure rather than traditional appetite-suppression mechanisms. Preclinical acceptable. Ex-China / global rights preferred.

CHRM4 Inhibitor

US/EU buyer target-interest mandate for CHRM4 Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.

COX / 5-LOX Inhibitor

US/EU buyer target-interest mandate for COX / 5-LOX Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.

FcRn Inhibitor

US/EU buyer target-interest mandate for FcRn Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.

IFN-gamma Inhibitor

US/EU buyer target-interest mandate for IFN-gamma Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.

JAK2 V617F Mutant-Selective Inhibitor

US/EU buyer target-interest mandate for JAK2 V617F Mutant-Selective Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.

LNK Inhibitor

US/EU buyer target-interest mandate for LNK Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.

AKT1 Inhibitor

US/EU buyer target-interest mandate for AKT1 Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.

APJ Antagonist

US/EU buyer target-interest mandate for APJ Antagonist programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.

BMP9 Recombinant Protein (mimic endogenous BMP9)

US/EU buyer target-interest mandate for BMP9 Recombinant Protein (mimic endogenous BMP9) programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.

CALR Mutant-Selective Inhibitor

US/EU buyer target-interest mandate for CALR Mutant-Selective Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.

Matriptase-2 Inhibitor

US/EU buyer target-interest mandate for Matriptase-2 Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.

Plasminogen Inhibitor

US/EU buyer target-interest mandate for Plasminogen Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.

Protein S Inhibitor

US/EU buyer target-interest mandate for Protein S Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.

SF3B1 Splicing Modulator

US/EU buyer target-interest mandate for SF3B1 Splicing Modulator programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.

TIE2 Inhibitor

US/EU buyer target-interest mandate for TIE2 Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.

TPO Receptor / MPL Inhibitor

US/EU buyer target-interest mandate for TPO Receptor / MPL Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.

Oral / Cyclic Peptides

US/EU buyer mandate to in-license oral peptide and cyclic peptide programs. No restriction on development stage or indication. Ex-China / global rights preferred.

Mutant CALR (Calreticulin)

US/EU buyer mandate to in-license programs targeting mutant CALR (calreticulin) for hematologic malignancies. Open to small molecule, biologic, or siRNA modalities; preclinical stage acceptable. Ex-China / global rights preferred.

BBB-Penetrant I&I / CNS Small Molecules

US/EU buyer seeking to in-license blood-brain-barrier (BBB)-penetrant immunology & inflammation (I&I) small molecules, or CNS small molecules for neurodegenerative diseases - particularly assets addressing targets in neuroinflammatory or neurometabolic pathways. Ex-China / global rights preferred.

Cardiovascular - Six Named Indications

Overseas buyer mandate to in-license programs treating cardiovascular disease across six named indications: cardiopulmonary disease, heart failure, atrial fibrillation, stroke, atherosclerosis, and pulmonary hypertension. Preclinical-stage assets acceptable; modality open.

MEK-RAF and KRAS-CYP A (small molecule / molecular glue)

European and American buyer mandate to in-license small-molecule and molecular glue programs targeting MEK-RAF and KRAS-CYP A. Pre-PCC (pre-preclinical-candidate) stage assets are explicitly in scope.

Oral Peptides - Autoimmune & Immune-Related Disease

European and American buyer mandate to in-license oral peptide programs targeting autoimmune and immune-related diseases at near-IND or clinical stage.

First-in-Class Autoimmune Antibodies

European and American buyer mandate to in-license first-in-class (FIC) autoimmune antibody programs at pre-PCC stage. Companion brief to the near-IND oral peptide mandate from the same buyers.

Anti-TRBV9 mAb or TRBV9/CD3 T-Cell Engager

European and American buyer mandate to in-license an IND-stage anti-TRBV9 monoclonal antibody, or a TRBV9/CD3 T-cell engager (TCE). Single-target brief with a firm IND-stage requirement.

TYK2 / JAK / dual TYK2-JAK Inhibitors

European and American buyer mandate to in-license TYK2, JAK, or dual TYK2/JAK small-molecule inhibitors. Preclinical-stage assets acceptable. Expect diligence on JH1 versus JH2 binding and on selectivity across the wider JAK family.

买方引进需求：寻求在炎症、免疫与纤维化领域具有潜力的项目。优先单克隆抗体或小分子，开发阶段在开发候选物（DC）至 IND 之间。目前没有明确的靶点清单，买方对各类机制的资产均持开放态度。

分子胶 / MGD / 非降解型分子胶（如 MEK-RAF、KRAS-CYPA）

买方引进需求：寻求小分子、分子胶及分子胶降解剂（MGD）项目。口服给药，优先每日一次。优先实体瘤，亦对 I&I、神经退行性疾病与肥胖持开放态度。要求已完成 FTO 并已提交化合物专利申请，机制成熟，患者筛选标准清晰，PD 定义明确，且在异种移植瘤模型中具备单药肿瘤退缩疗效。明确排除：针对 IKZF、GSPT1、WEE1、CK1a、CDK（CDK4 除外）、CCNE1、BTK、ROS1、ALK 的 MGD。

机制成熟，人群定义明确

与同一买方的分子胶需求配套：寻求任何阶段的 NSCLC 或 SCLC 资产，须具备成熟的作用机制（MOA）与定义明确的患者人群。要求患者筛选标准清晰、PD 定义明确。优先全球权益，可切分亚洲市场。

口服 TNF-α 与 TL1A 小分子抑制剂

欧美买方引进需求：寻求口服 TNF-α 与 TL1A 小分子抑制剂项目。临床前候选药物（PCC）之前阶段的资产明确在考虑范围内。

狂犬病疫苗（非 mRNA）

买方引进需求：寻求非 mRNA 狂犬病疫苗，理想阶段为 III 期或已获批上市。

带状疱疹疫苗（非 mRNA）

买方引进需求：寻求非 mRNA 带状疱疹疫苗，理想阶段为 III 期或已获批上市。与同一买方的非 mRNA 狂犬病疫苗需求配套。

体内 CAR-T（in vivo CAR-T）

买方引进需求：寻求血液肿瘤领域的体内（in vivo）CAR-T 项目。仅考虑临床阶段候选产品。

体内基因治疗（in vivo）

买方引进需求：寻求用于镰状细胞病（SCD）与 β 地中海贫血的体内（in vivo）基因治疗项目。仅考虑临床阶段候选产品。

体内基因治疗（in vivo）

买方引进需求：寻求用于 A 型与 B 型血友病的体内（in vivo）基因治疗项目。与 SCD / β 地中海贫血及家族性高胆固醇血症需求同属一份体内基因治疗简报。

体内基因治疗（in vivo）

买方引进需求：寻求用于家族性高胆固醇血症的体内（in vivo）基因治疗项目。与 SCD / β 地中海贫血及 A/B 型血友病需求同属一份体内基因治疗简报。